About SwanBio Therapeutics
SwanBio Therapeutics is a company based in Bala Cynwyd (United States) founded in 2017 was acquired by Freeline in June 2024.. SwanBio Therapeutics has raised $133 million across 3 funding rounds from investors including Freeline, Syncona and Mass General Brigham Ventures. The company has 47 employees as of December 31, 2021. SwanBio Therapeutics offers products and services including FLT201, Gene Therapy for Parkinson's, and AMN Therapy. SwanBio Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Bala Cynwyd, United States
- Employees 47 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Swanbio Therapeutics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SwanBio Therapeutics
SwanBio Therapeutics offers a comprehensive portfolio of products and services, including FLT201, Gene Therapy for Parkinson's, and AMN Therapy. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapy for Gaucher Disease to improve patient outcomes.
Treatment aimed at modifying Parkinson's disease progression.
First-in-class therapy for adrenomyeloneuropathy conditions.
Unlock access to complete
Unlock access to complete
Funding Insights of SwanBio Therapeutics
SwanBio Therapeutics has successfully raised a total of $133M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $56 million completed in May 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $56.0M
-
First Round
First Round
(14 Jan 2018)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2022 | Amount | Series B - SwanBio Therapeutics | Valuation | Syncona , Mass General Brigham Ventures |
|
| Apr, 2020 | Amount | Series A - SwanBio Therapeutics | Valuation | Syncona |
|
| Jan, 2018 | Amount | Series A - SwanBio Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in SwanBio Therapeutics
SwanBio Therapeutics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Freeline, Syncona and Mass General Brigham Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are managed via private equity by Syncona.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Gene therapy platform is developed for chronic disease treatments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by SwanBio Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - SwanBio Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Swanbio Therapeutics Comparisons
Competitors of SwanBio Therapeutics
SwanBio Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Swanbio Therapeutics
Frequently Asked Questions about SwanBio Therapeutics
When was SwanBio Therapeutics founded?
SwanBio Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is SwanBio Therapeutics located?
SwanBio Therapeutics is headquartered in Bala Cynwyd, United States. It is registered at Bala Cynwyd, Pennsylvania, United States.
Is SwanBio Therapeutics a funded company?
SwanBio Therapeutics is a funded company, having raised a total of $133M across 3 funding rounds to date. The company's 1st funding round was a Series A of $25M, raised on Jan 14, 2018.
How many employees does SwanBio Therapeutics have?
As of Dec 31, 2021, the latest employee count at SwanBio Therapeutics is 47.
What does SwanBio Therapeutics do?
SwanBio Therapeutics was founded in 2017 and is headquartered in Bala Cynwyd, United States. Focus is placed on developing adeno-associated virus (AAV)-based therapies for neurological disorders. Therapeutic genes are delivered directly to the central nervous system via AAV vectors to address disease mechanisms. Operations center on genetic interventions, with the lead candidate SBT101 designed to treat adrenomyeloneuropathy (AMN) through targeting of the ABCD1 gene mutation.
Who are the top competitors of SwanBio Therapeutics?
SwanBio Therapeutics's top competitors include Jazz Pharmaceuticals, Spark Therapeutics and BridgeBio.
What products or services does SwanBio Therapeutics offer?
SwanBio Therapeutics offers FLT201, Gene Therapy for Parkinson's, and AMN Therapy.